These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 21940787)

  • 21. Tumor Targeting with Novel 6-Substituted Pyrrolo [2,3-d] Pyrimidine Antifolates with Heteroatom Bridge Substitutions via Cellular Uptake by Folate Receptor α and the Proton-Coupled Folate Transporter and Inhibition of de Novo Purine Nucleotide Biosynthesis.
    Golani LK; Wallace-Povirk A; Deis SM; Wong J; Ke J; Gu X; Raghavan S; Wilson MR; Li X; Polin L; de Waal PW; White K; Kushner J; O'Connor C; Hou Z; Xu HE; Melcher K; Dann CE; Matherly LH; Gangjee A
    J Med Chem; 2016 Sep; 59(17):7856-76. PubMed ID: 27458733
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Biology and therapeutic applications of the proton-coupled folate transporter.
    Matherly LH; Schneider M; Gangjee A; Hou Z
    Expert Opin Drug Metab Toxicol; 2022 Oct; 18(10):695-706. PubMed ID: 36239195
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Novel 5-substituted pyrrolo[2,3-d]pyrimidines as dual inhibitors of glycinamide ribonucleotide formyltransferase and 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase and as potential antitumor agents.
    Wang Y; Mitchell-Ryan S; Raghavan S; George C; Orr S; Hou Z; Matherly LH; Gangjee A
    J Med Chem; 2015 Feb; 58(3):1479-93. PubMed ID: 25602637
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Substituted cysteine accessibility reveals a novel transmembrane 2-3 reentrant loop and functional role for transmembrane domain 2 in the human proton-coupled folate transporter.
    Wilson MR; Hou Z; Matherly LH
    J Biol Chem; 2014 Sep; 289(36):25287-95. PubMed ID: 25053408
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Synthesis and biological activity of 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl regioisomers as inhibitors of de novo purine biosynthesis with selectivity for cellular uptake by high affinity folate receptors and the proton-coupled folate transporter over the reduced folate carrier.
    Wang L; Cherian C; Kugel Desmoulin S; Mitchell-Ryan S; Hou Z; Matherly LH; Gangjee A
    J Med Chem; 2012 Feb; 55(4):1758-70. PubMed ID: 22243528
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Identification and functional impact of homo-oligomers of the human proton-coupled folate transporter.
    Hou Z; Kugel Desmoulin S; Etnyre E; Olive M; Hsiung B; Cherian C; Wloszczynski PA; Moin K; Matherly LH
    J Biol Chem; 2012 Feb; 287(7):4982-95. PubMed ID: 22179615
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Discovery of amide-bridged pyrrolo[2,3-d]pyrimidines as tumor targeted classical antifolates with selective uptake by folate receptor α and inhibition of de novo purine nucleotide biosynthesis.
    Xiang W; Dekhne A; Doshi A; O'Connor C; Hou Z; Matherly LH; Gangjee A
    Bioorg Med Chem; 2019 Dec; 27(23):115125. PubMed ID: 31679978
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Folate-appended cyclodextrin carrier targets ovarian cancer cells expressing the proton-coupled folate transporter.
    Saito S; Koya Y; Kajiyama H; Yamashita M; Kikkawa F; Nawa A
    Cancer Sci; 2020 May; 111(5):1794-1804. PubMed ID: 32154964
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Role of proton-coupled folate transporter in pemetrexed resistance of mesothelioma: clinical evidence and new pharmacological tools.
    Giovannetti E; Zucali PA; Assaraf YG; Funel N; Gemelli M; Stark M; Thunnissen E; Hou Z; Muller IB; Struys EA; Perrino M; Jansen G; Matherly LH; Peters GJ
    Ann Oncol; 2017 Nov; 28(11):2725-2732. PubMed ID: 28945836
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Concentrative Transport of Antifolates Mediated by the Proton-Coupled Folate Transporter (SLC46A1); Augmentation by a HEPES Buffer.
    Zhao R; Najmi M; Aluri S; Spray DC; Goldman ID
    Mol Pharmacol; 2018 Mar; 93(3):208-215. PubMed ID: 29326243
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The evolving biology of the proton-coupled folate transporter: New insights into regulation, structure, and mechanism.
    Hou Z; Gangjee A; Matherly LH
    FASEB J; 2022 Feb; 36(2):e22164. PubMed ID: 35061292
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Structural basis of antifolate recognition and transport by PCFT.
    Parker JL; Deme JC; Kuteyi G; Wu Z; Huo J; Goldman ID; Owens RJ; Biggin PC; Lea SM; Newstead S
    Nature; 2021 Jul; 595(7865):130-134. PubMed ID: 34040256
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Functional and mechanistic roles of the human proton-coupled folate transporter transmembrane domain 6-7 linker.
    Wilson MR; Hou Z; Wilson LJ; Ye J; Matherly LH
    Biochem J; 2016 Oct; 473(20):3545-3562. PubMed ID: 27514717
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hypermethylation of the human proton-coupled folate transporter (SLC46A1) minimal transcriptional regulatory region in an antifolate-resistant HeLa cell line.
    Diop-Bove NK; Wu J; Zhao R; Locker J; Goldman ID
    Mol Cancer Ther; 2009 Aug; 8(8):2424-31. PubMed ID: 19671745
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Properties of the Arg376 residue of the proton-coupled folate transporter (PCFT-SLC46A1) and a glutamine mutant causing hereditary folate malabsorption.
    Mahadeo K; Diop-Bove N; Shin D; Unal ES; Teo J; Zhao R; Chang MH; Fulterer A; Romero MF; Goldman ID
    Am J Physiol Cell Physiol; 2010 Nov; 299(5):C1153-61. PubMed ID: 20686069
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Design, synthesis and biological evaluation of novel pyrrolo[2,3-d]pyrimidine as tumor-targeting agents with selectivity for tumor uptake by high affinity folate receptors over the reduced folate carrier.
    Golani LK; Islam F; O'Connor C; Dekhne AS; Hou Z; Matherly LH; Gangjee A
    Bioorg Med Chem; 2020 Jun; 28(12):115544. PubMed ID: 32503687
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The membrane transport and polyglutamation of pralatrexate: a new-generation dihydrofolate reductase inhibitor.
    Visentin M; Unal ES; Zhao R; Goldman ID
    Cancer Chemother Pharmacol; 2013 Sep; 72(3):597-606. PubMed ID: 23881211
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Determinants of the activities of antifolates delivered into cells by folate-receptor-mediated endocytosis.
    Zhao R; Visentin M; Goldman ID
    Cancer Chemother Pharmacol; 2015 Jun; 75(6):1163-73. PubMed ID: 25847479
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Enhanced receptor-mediated endocytosis and cytotoxicity of a folic acid-desacetylvinblastine monohydrazide conjugate in a pemetrexed-resistant cell line lacking folate-specific facilitative carriers but with increased folate receptor expression.
    Zhao R; Diop-Bove N; Goldman ID
    Mol Pharmacol; 2014 Feb; 85(2):310-21. PubMed ID: 24249723
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Identification of Tyr residues that enhance folate substrate binding and constrain oscillation of the proton-coupled folate transporter (PCFT-SLC46A1).
    Visentin M; Unal ES; Najmi M; Fiser A; Zhao R; Goldman ID
    Am J Physiol Cell Physiol; 2015 Apr; 308(8):C631-41. PubMed ID: 25608532
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.